The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies.
B. Basu
No relevant relationships to disclose
J. E. Ang
No relevant relationships to disclose
D. Crawley
No relevant relationships to disclose
E. Folkerd
Other Remuneration - Institute of Cancer Research, Research Reward for Inventors Abiraterone)
D. Sarker
No relevant relationships to disclose
M. Blanco-Codesido
No relevant relationships to disclose
K. Moran
No relevant relationships to disclose
S. Wan
No relevant relationships to disclose
N. Dobbs
No relevant relationships to disclose
F. Raynaud
Other Remuneration - Institute of Cancer Research, Research Reward for Inventors (Abiraterone)
S. R. D. Johnston
No relevant relationships to disclose
M. Dowsett
Other Remuneration - Institute of Cancer Research, Rewards for Inventors scheme Abiraterone)
A. N. J. Tutt
No relevant relationships to disclose
J. F. Spicer
No relevant relationships to disclose
C. Swanton
No relevant relationships to disclose
J. S. De Bono
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Johnson & Johnson (U)
Honoraria - Johnson & Johnson